Screener
Kyverna Therapeutics, Inc. KYTX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219397
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Payments for offering costs | (69) | (76) |
| Taxes paid related to net share settlement of restricted stock units | (189) | — |
| Net cash used in financing activities | (101) | (414) |
| Net decrease in cash and cash equivalents and restricted cash | (91,899) | (39,751) |
| Cash, cash equivalents and restricted cash, at beginning of period | 124,644 | 97,173 |
| Cash, cash equivalents and restricted cash, at end of period | $32,745 | $57,422 |
| Reconciliation of cash, cash equivalents and restricted cash to statement of financial position | ||
| Cash and cash equivalents | 32,194 | 56,865 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Kyverna Therapeutics, Inc.'s net change in cash?
- Kyverna Therapeutics, Inc. (KYTX) reported net change in cash of -$91.9M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s net change in cash changed year-over-year?
- Kyverna Therapeutics, Inc.'s net change in cash decreased by 131.2% year-over-year, from -$39.75M to -$91.9M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Kyverna Therapeutics, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude